Anti-virulence Agents Research Articles

Antimicrobial and anti-virulence activities of 4-shogaol from grains of paradise against gram-negative bacteria: Integration of experimental and computational methods

Ethnopharmacological relevanceBacterial resistance to antibiotics is a growing global concern, highlighting the urgent need for new antimicrobial candidates. Aframomum melegueta was traditionally used for combating urinary tract and soft tissue infections, which implies its potential as an antimicrobial agent. Aim of studyThis study was designed to explore the antibacterial and anti-virulence capabilities of 4-shogaol isolated from A. melegueta seeds versus gram-negative bacteria: Serratia marcescens, Klebsiella pneumoniae, Acinetobacter baumannii, and the clinically important pathogen Pseudomonas aeruginosa. Materials and methods4-Shogeol was isolated from A. melegueta seeds and its MICs were determined for Acinetobacter baumannii (ATCC-17978), Pseudomonas aeruginosa (ATCC-27853), Klebsiella pneumoniae (ATCC-700603), and Serratia marcescens clinical isolate. The anti-efflux activity and effect on the bacterial cell membrane for the compound were evaluated. Furthermore, the anti-virulence activities of the compound were evaluated. The effects of 4-shogeol at sub-MIC on bacterial motility, biofilm formation, and production of virulent enzymes and pigments were assessed. The anti-quorum sensing activities of 4-shogeol were evaluated virtually and by quantification its effect on the expression of quorum sensing encoding genes. The in vivo protection assay was conducted to evaluate the effect of 4-shogaol on the P. aeruginosa capacity to induce pathogenesis in mice. Finally, the effect of shogaol-antibiotics combination was assessed. ResultsThe research revealed that 4-shogaol's antibacterial action primarily involves disrupting the bacterial cell membrane and efflux pumps. It also exhibited significant anti-virulence effects by reducing biofilm development and repressing virulence factors production, effectively protecting mice against P. aeruginosa infection. Furthermore, when combined with antibiotics, 4-shogaol demonstrated synergistic effects, leading to reduced minimum inhibitory concentrations (MICs) against P. aeruginosa. Its anti-virulence properties were linked to its ability to disrupt bacterial quorum sensing (QS) mechanisms, as evidenced by its interaction with QS receptors and downregulation of QS-related genes. Notably, in silico analysis indicated that 4-shogaol exhibited strong binding affinity to different P. aeruginosa QS targets. ConclusionThese findings suggest that 4-shogaol holds promise as an effective anti-virulence agent that can be utilized in combination with antibiotics for treating severe infections caused by gram-positive bacteria.

Curcumin Aattenuates the Expression of Metalloprotease (AHA_0978) and Serine Protease (AHA_3857) Genes in Aeromonas Hydrophila.

Aeromonas hydrophila is a pathogenic bacterium responsible for various infections in humans and animals. Bacterial exoproteases are considered an important determinant in the pathogenicity of A. hydrophila. Serine protease and metalloprotease, that are regulated by the bacterial Quorum sensing (QS) system are important virulent factors in the pathogenicity of A. hydrophila. Anti-QS potential of curcumin has been reported, previously. In this work, we characterized the effect of curcumin on the expression of the metalloprotease and serine protease genes in A. hydrophila. The minimum inhibitory concentration (MIC) of curcumin was measured by the agar macro-dilution method and a sub-inhibitory concentration (1/2 MIC) was used in subsequent experiments. The expression level of the metalloprotease and serine protease genes among the treated and control bacteria was evaluated using quantitative PCR (qPCR) assay. Bacterial proteolytic activity was also measured by skim milk agar plate assay. MIC of curcumin for bacterial strain was 1024 μg/ml curcumin, and at 512 µg/mL (1/2 MIC) it remarkably attenuated the expression of the metalloprotease and serine protease genes up to 66 and 77%, respectively. Also, the proteolytic activity of A. hydrophila was considerably reduced by curcumin. Due to the promising inhibitory effect on bacterial proteolysis, curcumin could be considered an anti-virulence agent against A. hydrophila.

Carbon quantum dots derived from resveratrol enhances anti-virulence activity against Pseudomonas aeruginosa

Resveratrol (Res), one phenolic compound derived from many kinds of fruits, has been shown to possess anti-virulence activity against the food spoilage bacterium Pseudomonas aeruginosa. However, the high usage and low activity limit its widespread application in food industry. In this study, Res was prepared into resveratrol carbon quantum dots (CQDRes) and the anti-virulence activity and anti-virulence mechanism of CQDRes were revealed for the first time. Exposure to CQDRes at 100 µg/mL significantly inhibited chemotaxis and the production of elastase, pyocyanin, rhamnolipid, and biofilms on the interface, and this inhibitory effect was higher than that of Res. Comprehensive transcriptome, proteomics, and parallel reaction monitoring analyses indicated that the pqs system of P. aeruginosa PAO1 was seriously disrupted after treatment with CQDRes while Res exposure had no such disrupted effect. The disrupted pqs system notably down-regulated the expressions of virulence-related genes and reduced the secretion of PQS-related signal molecules and pathogenicity of P. aeruginosa PAO1. The pqsC-knockout assay presented the reduced production of virulence factors and further confirmed the dysfunction of pqs system induced by CQDRes. These data indicated that CQDRes has the potential to function as an anti-virulence agent to defending against the foodborne pathogen P. aeruginosa.

3-Hydroxypyridin-4(1H)-one Derivatives as pqs Quorum Sensing Inhibitors Attenuate Virulence and Reduce Antibiotic Resistance in Pseudomonas aeruginosa.

The development of quorum sensing inhibitors capable of decreasing the production of virulence factors is an effective strategy to overcome resistance in Pseudomonas aeruginosa due to the less selective pressure exerted on bacteria. In this study, a series of 3-hydroxypyridin-4(1H)-one derivatives bearing a 4-aminomethyl-1,2,3-triazole linker were designed and synthesized as antivirulence agents against P. aeruginosa. The most potent derivative 16e was identified as a selective inhibitor of the pqs system (IC50 = 3.7 μM) and its related virulence factor pyocyanin (IC50 = 2.7 μM). In addition, 16e exhibited moderate biofilm inhibition and significant inhibition of P. aeruginosa motility phenotypes with low cytotoxicity. Compound 16e showed an obvious antibacterial synergistic effect in combination with antibiotics such as ciprofloxacin and tobramycin in in vitro and in vivo Caenorhabditis elegans infection models. Overall, the excellent antivirulence properties of compound 16e make it a potential antibiotic adjuvant for the treatment of P. aeruginosa infections that may be advanced into preclinical development in the future.

Evaluation of Azithromycin and Fenugreek Oil as Anti-virulence Agents against Stenotrophomonas maltophilia MultiDrug Resistant Clinical Isolates

Evaluation of Azithromycin and Fenugreek Oil as Anti-virulence Agents against Stenotrophomonas maltophilia MultiDrug Resistant Clinical Isolates

Interception of Epoxide ring to quorum sensing system in Enterococcus faecalis and Staphylococcus aureus

Quorum sensing inhibitor (QSI) has been attracting attention as anti-virulence agent which disarms pathogens of their virulence rather than killing them. QSI marking cyclic peptide-mediated QS in Gram-positive bacteria is an effective tool to overcome the crisis of antibiotic-dependent chemotherapy due to the emergence of drug resistance strain, e.g., methicillin resistant Staphylococcus aureus (MRSA) and Vancomycin resistant Enterococci (VRE). From a semi-large-scale screening thus far carried out, two Epoxide compounds, Ambuic acid and Synerazol, have been found to efficiently block agr and fsr QS systems, suggesting that the Epoxide group is involved in the mode of action of these QSIs. To address this notion, known natural Epoxide compounds, Cerulenin and Fosfomycin were examined for QSI activity for the agr and fsr systems in addition to in silico and SAR studies. As a result, most of investigated Epoxide containing antibiotics correlatively interfere with QSI activity for the agr and fsr systems under sublethal concentrations.

Harnessing the combined effect of antivirulence agent trans-chalcone with bactericidal curcumin against sortase A enzyme to tackle Gram-positive bacterial infections.

Gram-positive bacteria are responsible for a wide range of infections in humans. In most Gram-positive bacteria, sortase A plays a significant role in attaching virulence factors to the bacteria's cell wall. These cell surface proteins play a significant role in virulence and pathogenesis. Even though antibiotics are available to treat these infections, there is a continuous search for an alternative strategy due to an increase in antibiotic resistance. Thus, using anti-sortase drugs to combat these bacterial infections may be a promising approach. Here, we describe a method for targeting Gram-positive bacterial infection by combining curcumin and trans-chalcone as sortase A inhibitors. We have used curcumin and trans-chalcone alone and in combination as a sortase A inhibitor. We have seen ~78%, ~43%, and ~94% inhibition when treated with curcumin, trans-chalcone, and a combination of both compounds, respectively. The compounds have also shown a significant effect on biofilm formation, IgG binding, protein A recruitment, and IgG deposition. We discovered that combining curcumin and trans-chalcone is more effective against Gram-positive bacteria than either compound alone. The present work demonstrated that a combination of these natural compounds could be used as an antivirulence therapy against Gram-positive bacterial infection.

Identification of an antivirulence agent targeting the master regulator of virulence genes in Staphylococcus aureus.

The emergence of bactericidal antibiotic-resistant strains has increased the demand for alternative therapeutic agents, such as antivirulence agents targeting the virulence regulators of pathogens. Staphylococcus aureus exoprotein expression (sae) locus, the master regulator of virulence gene expression in multiple drug-resistant S. aureus, is a promising therapeutic target. In this study, we screened a small-molecule library using a SaeRS green fluorescent protein (GFP)-reporter that responded to transcription controlled by the sae locus. We identified the compound, N-(2-methylcyclohexyl)-11-oxo-10,11-dihydrodibenzo[b,f][1,4]thiazepine-8-carboxamide (SKKUCS), as an efficient repressor of sae-regulated GFP activity. SKKUCS inhibited hemolysin production and reduced α-hemolysin-mediated cell lysis. Moreover, SKKUCS substantially reduced the expression levels of various virulence genes controlled by the master regulators, sae, and the accessory gene regulator (agr), demonstrating its potential as an antivirulence reagent targeting the key virulence regulators. Furthermore, autokinase inhibition assay and molecular docking suggest that SKKUCS inhibits the kinase activity of SaeS and potentially targets the active site of SaeS kinase, possibly inhibiting ATP binding. Next, we evaluated the efficacy and toxicity of SKKUCS in vivo using murine models of staphylococcal intraperitoneal and skin infections. Treatment with SKKUCS markedly increased animal survival and significantly decreased the bacterial burden in organs and skin lesion sizes. These findings highlight SKKUCS as a potential antivirulence drug for drug-resistant staphylococcal infections.

Anti-Biofilm Activity of Carnosic Acid from Salvia rosmarinus against Methicillin-Resistant Staphylococcus aureus.

The Salvia rosmarinus "Eretto Liguria" ecotype was studied as a source of valuable bioactive compounds. LC-MS analysis of the methanolic extract underlined the presence of diterpenoids, triterpenoids, polyphenolic acids, and flavonoids. The anti-virulence activity of carnosic acid along with the other most abundant compounds against methicillin-resistant Staphylococcus aureus (MRSA) was evaluated. Only carnosic acid induced a significant reduction in the expression of agrA and rnaIII genes, which encode the key components of quorum sensing (QS), an intracellular signaling mechanism controlling the virulence of MRSA. At a concentration of 0.05 mg/mL, carnosic acid inhibited biofilm formation by MRSA and the expression of genes involved in toxin production and made MRSA more susceptible to intracellular killing, with no toxic effects on eukaryotic cells. Carnosic acid did not affect biofilm formation by Pseudomonas aeruginosa, a human pathogen that often coexists with MRSA in complex infections. The selected ecotype showed a carnosic acid content of 94.3 ± 4.3 mg/g. In silico analysis highlighted that carnosic acid potentially interacts with the S. aureus AgrA response regulator. Our findings suggest that carnosic acid could be an anti-virulence agent against MRSA infections endowed with a species-specific activity useful in multi-microbial infections.

L-glutamine protects against enterohemorrhagic Escherichia coli infection by inhibiting bacterial virulence and enhancing host defense concurrently.

Enterohemorrhagic Escherichia coli (EHEC) can colonize the gastrointestinal tract and cause bloody diarrhea in children. Previous studies showed that its pathogenesis could be mediated by metabolites from both the host and microbiota. L-Glutamine (Gln) was found to be depleted in intestinal tissues as the main energy source according to previous studies. Hence, we aimed to determine the effects of Gln on EHEC infection and its underlying mode of action. In this study, a Gln-limited signal was found to activate the type 3 secretion system (T3SS), which is crucial for EHEC infection via perturbation of central metabolism. By shifting the phosphorylation of NtrC, a key regulator in bacterial nitrogen metabolism, Gln stimulates ler transcripts in a σS-PchA-dependent manner. Our in vivo experiments further demonstrated that Gln supplementation can reduce EHEC colonization in the gastrointestinal tract by repressing T3SS. Moreover, Gln could further attenuate bacterial infection by boosting host defense, which might be dependent on multiple pathways. Besides, our experiments demonstrated that Gln did not induce Shiga-like toxin (Stx) production or cause impairment of gut flora. In conclusion, our study presented evidence that Gln could act against EHEC infection by reducing bacterial virulence and strengthening host defense. Therefore, Gln serves as a promising therapeutic agent for EHEC infection. IMPORTANCE The type 3 secretion system (T3SS) was obtained in many Gram-negative bacterial pathogens, and it is crucial for their pathogenesis. Environmental signals were found to be involved in the expression regulation of T3SS, which was vital for successful bacterial infection in the host. Here, we discovered that L-glutamine (Gln), the most abundant amino acid in the human body, could repress enterohemorrhagic Escherichia coli (EHEC) T3SS expression via nitrogen metabolism and therefore had potential as an antivirulence agent. Our in vitro and in vivo evidence demonstrated that Gln could decline EHEC infection by attenuating bacterial virulence and enhancing host defense simultaneously. We repurpose Gln as a potential treatment for EHEC infection accordingly.

Echinacoside, a promising sortase A inhibitor, combined with vancomycin against murine models of MRSA-induced pneumonia.

Methicillin-resistant Staphylococcus aureus (MRSA) is a pathogenic bacterium responsible for a range of severe infections, such as skin infections, bacteremia, and pneumonia. Due to its antibiotic-resistant nature, current research focuses on targeting its virulence factors. Sortase A (SrtA) is a transpeptidase that anchors surface proteins to the bacterial cell wall and is involved in adhesion and invasion to host cells. Through fluorescence resonance energy transfer (FRET), we identified echinacoside (ECH), a natural polyphenol, as a potential SrtA inhibitor with an IC50 of 38.42μM in vitro. It was demonstrated that ECH inhibited SrtA-mediated S. aureus fibrinogen binding, surface protein A anchoring, and biofilm formation. The fluorescence quenching assay determined the binding mode of ECH to SrtA and calculated the KA-binding constant of 3.09 × 105L/mol, demonstrating the direct interaction between the two molecules. Molecular dynamics simulations revealed that ECH-SrtA interactions occurred primarily at the binding sites of A92G, A104G, V168A, G192A, and R197A. Importantly, the combination of ECH and vancomycin offered protection against murine models of MRSA-induced pneumonia. Therefore, ECH may serve as a potential antivirulence agent against S. aureus infections, either alone or in combination with vancomycin.

Sulisobenzone is a potent inhibitor of the global transcription factor Cra

Transcription is carried out by the RNA polymerase and is regulated through a series of interactions with transcription factors. Catabolite activator repressor (Cra), a LacI family transcription factor regulates the virulence gene expression in Enterohaemorrhagic Escherichia coli (EHEC) and thus is a promising drug target for the discovery of antivirulence molecules. Here, we report the crystal structure of the effector molecule binding domain of Cra from E. coli (EcCra) in complex with HEPES molecule. Based on the EcCra-HEPES complex structure, ligand screening was performed that identified sulisobenzone as an potential inhibitor of EcCra. The electrophoretic mobility shift assay (EMSA) and in vitro transcription assay validated the sulisobenzone binding to EcCra. Moreover, the isothermal titration calorimetry (ITC) experiments demonstrated a 40-fold higher binding affinity of sulisobenzone (KD 360 nM) compared to the HEPES molecule. Finally, the sulisobenzone bound EcCra complex crystal structure was determined to elucidate the binding mechanism of sulisobenzone to the effector binding pocket of EcCra. Together, this study suggests that sulisobenzone may be a promising candidate that can be studied and developed as an effective antivirulence agent against EHEC.

Study the Antibacterial Mechanism of Diclofenac and its Activity Alone or Combined with Ciprofloxacin in Treating Urinary Tract Infection

This study aimed to compare the effects of diclofenac, ciprofloxacin and their combination groups on urine tract infection (U.T.I.s) caused by resistance E coli 0157 H7 in vitro and in vivo. Two hundred urine samples were collected from adult women patients suffering from U.T.I.s from February 2022 to July 2022. The urine specimen was cultured on the blood agar and then incubated at 37°C for (1-2) days; MacConkey agar is the media used for determining the biochemistry results, and identification by Rapidchek test which was performed on typical colonies from the selective plate. The M.I.C effect of Diclofenac began at (25600µg/ml) against resistance E coli 0157H7 while M.I.C of ciprofloxacin it was at (0.96mg/ml), but M.I.C of a combination between (diclofenacn+ciprofloxacin) it was at (400+0.48) mg/ml. Resistance induction assay,with the ciprofloxacin has increased four times, while with the diclofenac has doubled, whilst the combination between (diclofenacn+ciprofloxacin) has no changed after 21 days, according to M.I.C.in the time-kill assay, it was proved that the ciprofloxacin and the combination between (diclofenacn+ciprofloxacin) works after 6 hours, compared to the diclofenac, which started to reduce bacterial counting after 40. After that, the examination was carried out by scanning electronic microscope (S.E.M.) to exam the mechanics of diclofenac,work which was found that it was works as anti-biofilm In this study, forty-eighth (48) rabbits were used and divided into six groups as follow positive control (P.C.), negative control (N.C.), diclofenac (D.C.) in 1mg/kg group, ciprofloxacin (C.I.P.)in7mg/kg group, combination (ciprofloxacin 3.5 mg/kg+diclofenac1mg/kg)COM1 group and combination (ciprofloxacin 1.75 mg/kg+diclofenac1mg/kg) com2 All animals (injected with 0.1 ml in CFU E coli 0157 H7 by urinary catheterization route excepting negative control all group excepting negative control resulted in a significant increase in pus cell, epithelium cell concentration in the urine after three days E coli 0157 H7 infection comparison with negative control while in all experimental period after (14 days) showed no significant (P < 0.05) between positive control (P.C.) and diclofenac treated groups but combination COM1 group and com2 decrease significantly (P< 0.05) after (seven and fourteen) days comparison with positive control. diclofenac can be combined with antibiotics as an anti-virulence agent, enhancing the immune system's ability to eradicate infection

Derivative of aminoresin as potent anti-virulence agent: Synthesis, spectral (FT-IR, UV, NMR) analysis, molecular docking, effect of polar solvation dynamics, and quantum chemical investigation

This work undertakes a comprehensive study encompassing the synthesis, spectral characterization (FT-IR, UV, 1HNMR , 13CNMR), exploration of polar solvation dynamics (DMSO, EtOH, MeOH) on the molecular structure, quantum chemical calculations, topological (ELF, NCI) analysis, and molecular docking investigation. The focal point is a derivative of amino terpolymer resin, synthesized via the condensation of 4,4′-diaminodiphenylmethane, 8-hydroxyquinoline, and formaldehyde (DHQF). Thorough examination of the compound was conducted to evaluate its responsiveness in varying solvents and investigate its viability as a key candidate for antivirulent therapy against toxins from Vibrio cholerae and Salmonella enterica. Simulation of solvation dynamics underscored the compound's robust thermodynamic stability even at lower temperatures. Primary vibrations noted within the compound encompassed CH, OH, NH, CH2, and CN vibrations, whereas UV spectroscopy unveiled an electronic shift from HOMO to LUMO, featuring peak absorption at 292.77 nm, influenced by its interaction with DMSO. The molecular docking analysis reveals the terpolymer's significant bioactivity against proteins 7EE6 (affinity: −6.7 kcal/mol) and 5V6f (affinity: -7.1 kcal/mol) associated with V. cholerae and S. enterica. The binding affinity of DHQF with S. enterica toxin protein (PDB: 7EE6) is comparable to that of standard drug Ciprofloxacin (affinity: −6.9 kcal/mol) and the toxin protein. However, the binding affinity between DHQF and V. cholerae toxin protein 5V5F considerably surpasses the binding affinity (−4.6 kcal/mol) between Doxycycline and the toxin protein. More so, the complex shows close binding affinities to both proteins and a higher number of conventional hydrogen bonds, this formed multiple favorable interactions, particularly conventional hydrogen bonds, contributing significantly to the stability of the ligand-protein complexes. In conclusion, the analyzed terpolymer displayed favorable qualities and interactions, which establish it as a strong candidate for addressing the targeted V. cholerae and S. enterica pathogens. These findings highlight the compound's impressive stability and its potential for various therapeutic applications in different areas.

Relocating Glyceryl Trinitrate as an Anti-Virulence Agent against Pseudomonas aeruginosa and Serratia marcescens: Insights from Molecular and In Vivo Investigations.

The problem of antibiotic resistance is a global critical public health concern. In light of the threat of returning to the pre-antibiotic era, new alternative approaches are required such as quorum-sensing (QS) disruption and virulence inhibition, both of which apply no discernible selective pressure on bacteria, therefore mitigating the potential for the development of resistant strains. Bearing in mind the significant role of QS in orchestrating bacterial virulence, disrupting QS becomes essential for effectively diminishing bacterial virulence. This study aimed to assess the potential use of sub-inhibitory concentration (0.25 mg/mL) of glyceryl trinitrate (GTN) to inhibit virulence in Serratia marcescens and Pseudomonas aeruginosa. GTN could decrease the expression of virulence genes in both tested bacteria in a significant manner. Histopathological study revealed the ability of GTN to alleviate the congestion in hepatic and renal tissues of infected mice and to reduce bacterial and leukocyte infiltration. This study recommends the use of topical GTN to treat topical infection caused by P. aeruginosa and S. marcescens in combination with antibiotics.

Structural biology and functional features of phage-derived depolymerase Depo32 on Klebsiella pneumoniae with K2 serotype capsular polysaccharides.

Hypervirulent Klebsiella pneumoniae with capsular polysaccharides (CPSs) causes severe nosocomial- and community-acquired infections. Phage-derived depolymerases can degrade CPSs from K. pneumoniae to attenuate bacterial virulence, but their antimicrobial mechanisms and clinical potential are not well understood. In the present study, Klebsiella phage GH-K3-derived depolymerase Depo32 (encoded by gene gp32) was identified to exhibit high efficiency in specifically degrading the CPSs of K2 serotype K. pneumoniae. The cryo-electron microscopy structure of trimeric Depo32 at a resolution up to 2.32 Å revealed potential catalytic centers in the cleft of each of the two adjacent subunits. K. pneumoniae subjected to Depo32 became more sensitive to phagocytosis by RAW264.7 cells and activated the cells by the mitogen-activated protein kinase signaling pathway. In addition, intranasal inoculation with Depo32 (a single dose of 200 µg, 20 µg daily for 3 days, or in combination with gentamicin) rescued all C57BL/6J mice infected with a lethal dose of K. pneumoniae K7 without interference from its neutralizing antibody. In summary, this work elaborates on the mechanism by which Depo32 targets the degradation of K2 serotype CPSs and its potential as an antivirulence agent. IMPORTANCE Depolymerases specific to more than 20 serotypes of Klebsiella spp. have been identified, but most studies only evaluated the single-dose treatment of depolymerases with relatively simple clinical evaluation indices and did not reveal the anti-infection mechanism of these depolymerases in depth. On the basis of determining the biological characteristics, the structure of Depo32 was analyzed by cryo-electron microscopy, and the potential active center was further identified. In addition, the effects of Depo32 on macrophage phagocytosis, signaling pathway activation, and serum killing were revealed, and the efficacy of the depolymerase (single treatment, multiple treatments, or in combination with gentamicin) against acute pneumonia caused by Klebsiella pneumoniae was evaluated. Moreover, the roles of the active sites of Depo32 were also elucidated in the in vitro and in vivo studies. Therefore, through structural biology, cell biology, and in vivo experiments, this study demonstrated the mechanism by which Depo32 targets K2 serotype K. pneumoniae infection.

Evaluating the Antibacterial and Antivirulence Activities of Floxuridine against Streptococcus suis.

Streptococcus suis is an emerging zoonotic pathogen that can cause fatal diseases such as meningitis and sepsis in pigs and human beings. The overuse of antibiotics is leading to an increased level of resistance in S. suis, and novel antimicrobial agents or anti-virulence agents for the treatment of infections caused by S. suis are urgently needed. In the present study, we investigated the antibacterial activity, mode of action and anti-virulence effects of floxuridine against S. suis. Floxuridine showed excessive antibacterial activity against S. suis both in vivo and in vitro; 4 × MIC of floxuridine could kill S. suis within 8 h in a time-kill assay. Meanwhile, floxuridine disrupted the membrane structure and permeability of the cytoplasmic membrane. Molecular docking revealed that floxuridine and SLY can be directly bind to each other. Moreover, floxuridine effectively inhibited the hemolytic capacity and expression levels of the virulence-related genes of S. suis. Collectively, these results indicate that the FDA-approved anticancer drug floxuridine is a promising agent and a potential virulence inhibitor against S. suis.

Coupling a Virulence-Targeting Moiety with Ru-Based AMP Mimics Efficiently Improved Its Anti-Infective Potency and Therapeutic Index.

The surge of antibiotic resistance in Staphylococcus aureus calls for novel drugs that attack new targets. Developing antimicrobial peptides (AMPs) or antivirulence agents (AvAs) is a promising strategy to tackle this challenge. However, AMPs, which kill bacteria by disrupting cell membranes, suffer from low stability and high synthesis cost, while AvAs, which inhibit toxin secretion, have relatively poor bactericidal activity. Here, to address their respective shortcomings, we combined these two different antibacterial activities on the same molecular scaffold and developed a Ru-based metalloantibiotic, termed Ru1. Notably, Ru1 exerted remarkable bactericidal activity (MICS = 460 nM) and attenuated bacterial virulence as well. Mechanistic studies demonstrated that Ru1 had two independent targets: CcpA and bacterial membrane integrity. Based on its dual mechanism of action, Ru1 effectively overcame S. aureus resistance and showed high efficacy in a mouse infection model against S. aureus. This study provides a promising approach to confronting bacterial infections.

The inhibition effect and mechanism of litsea cubeba essential oil on the hemolytic activity of listeriolysin O

This study investigated the use of Litsea cubeba essential oil (LC-EO) as an anti-virulence agent targeting listeriolysin O (LLO) of Listeria monocytogenes (L. monocytogenes). The hemolysis assay showed a significant decrease in the hemolytic activity of LLO by 90.7% and 70.2% after exposure to 500 μg mL−1 LC-EO or 700 μg mL−1 citral (the main component of LC-EO), respectively. This suggested that citral plays a major role in the anti-virulence function against LLO. The experiments including UV–visible absorption spectroscopy, fluorescence quenching and three-dimensional fluorescence spectroscopy demonstrated that exposure to citral leads to significant changes in the conformation of LLO, potentially resulting in the unfolding of its structure and the formation of a ground-state complex. Synchronous fluorescence spectra analysis indicated that the binding site of citral could be the undecapeptide region of LLO. Additionally, the results of molecular docking and the acid-base effect experiment of different aldehydes and phenols revealed that the cysteine residue of LLO and the α, β-unsaturated aldehyde of citral are likely to form a covalent bond through Michael addition. This interaction is believed to be the primary reason for the loss of hemolytic activity. As a result, this work provides a new approach for the development of LLO-targeting anti-virulence agents and holds promise for expanding the application of LC-EO in the field of food microbiological safety.

SaeR as a novel target for antivirulence therapy against Staphylococcus aureus

ABSTRACT Staphylococcus aureus is a major human pathogen responsible for a wide range of clinical infections. SaeRS is one of the two-component systems in S. aureus that modulate multiple virulence factors. Although SaeR is required for S. aureus to develop an infection, inhibitors have not been reported. Using an in vivo knockdown method, we demonstrated that SaeR is targetable for the discovery of antivirulence agent. HR3744 was discovered through a high-throughput screening utilizing a GFP-Lux dual reporter system driven by saeP1 promoter. The antivirulence efficacy of HR3744 was tested using Western blot, Quantitative Polymerase Chain Reaction, leucotoxicity, and haemolysis tests. In electrophoresis mobility shift assay, HR3744 inhibited SaeR-DNA probe binding. WaterLOGSY-NMR test showed HR3744 directly interacted with SaeR’s DNA-binding domain. When SaeR was deleted, HR3744 lost its antivirulence property, validating the target specificity. Virtual docking and mutagenesis were used to confirm the target’s specificity. When Glu159 was changed to Asn, the bacteria developed resistance to HR3744. A structure–activity relationship study revealed that a molecule with a slight modification did not inhibit SaeR, indicating the selectivity of HR3744. Interestingly, we found that SAV13, an analogue of HR3744, was four times more potent than HR3744 and demonstrated identical antivirulence properties and target specificity. In a mouse bacteraemia model, both HR3744 and SAV13 exhibited in vivo effectiveness. Collectively, we identified the first SaeR inhibitor, which exhibited in vitro and in vivo antivirulence properties, and proved that SaeR could be a novel target for developing antivirulence drugs against S. aureus infections.